Showing 5131-5140 of 6036 results for "".
- AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Sciencehttps://modernod.com/news/aivita-biomedicals-stem-cell-therapeutic-in-vision-loss-published-in-investigative-ophthalmology-vision-science/2478398/AIVITA Biomedical announced the publication of the peer-reviewed manuscript, “Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,” in the journal Investigative Ophthalmology & Visual Science. The
- Regeneron Asks FDA to Approve Emergency Use of REGN-COV2 for COVID-19https://modernod.com/news/regeneron-asks-fda-to-approve-emergency-use-of-regn-cov2-for-covid-19/2478394/Regeneron Pharmaceuticals said that it submitted a request to the FDA seeking emergency-use authorization for its REGN-COV2 investigational antibody combination for the treatment of COVID-19. REGN-COV2 is a combination of two monoclonal antibodies, REGN10933 and REGN10987, which has been designed
- Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-2020-and-continues-commitment-to-improving-worldwide-access-to-eye-care/2478392/Alcon celebrates World Sight Day through its corporate giving and company-led initiatives focused on improving access to quality eye care. In the spirit of this year’s theme, “Hope in Sight,” Alcon associates will help spark donations to global nonprofit organizations that advance eye health. The
- GSK, Vir Biotechnology Move Anti-SARS-CoV-2 Monoclonal Antibody Into Phase 3https://modernod.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/GlaxoSmithKline and partner Vir Biotechnology announced that the COMET-ICE study evaluating VIR-7831 as an early treatment for COVID-19 patients deemed to be at high risk of hospitalization will proceed into phase 3 testing, with preliminary results coming possibly before the end of this year. Th
- Alcon to Showcase Innovations at #Academy20 that Support Recovery and Growth for Eye Care Practiceshttps://modernod.com/news/alcon-to-showcase-innovations-at-academy20-that-support-recovery-and-growth-for-eye-care-practices/2478379/Alcon will highlight leading innovations and clinical research at the 2020 American Academy of Optometry (#Academy20) meeting taking place virtually from October 7-22, 2020. The company’s virtual program will feature updates on its most important innovations, including Precision1 one-day contact
- Sun Ophthalmics to Present E-Posters at AAOpthttps://modernod.com/news/sun-ophthalmics-to-present-e-posters-at-aaopt/2478370/Sun Ophthalmics announced that is will be present several e-posters at the upcoming virtual AAOpt meeting being held this week. Author Presentation October 7, 4-6 pm, Session: Anterior Segment I Toyos M, Shen Lee B, Schechter B, Ogundele A, Gupta P, K
- TearSolutions Announces Results From Primary Sjögren’s Syndrome Trial and Appoints Anil Asrani President and CEOhttps://modernod.com/news/tearsolutions-announces-results-from-primary-sjocc88grens-syndrome-trial-and-appoints-anil-asrani-president-and-ceo/2478369/TearSolutions announced the completion and preliminary outcomes of a phase 1/2 trial of Lacripep in Primary Sjögren’s Syndrome (PSS) patients. The trial was designed to test proof of concept and optimize the design f
- Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitishttps://modernod.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/Tarsius Pharma announced that the GADOT 20/20 trial of its novel TRS01 drug for treating active anterior noninfectious uveitis, demonstrated significant improvement in critical measures such as Anterior Chamber Cells, pain reduction and increased visual acuity. The GADOT 20/20 trial was a
- Beovu Now Available in Canada, Receives Positive Reimbursement Recommendationhttps://modernod.com/news/beovu-now-available-in-canada-receives-positive-reimbursement-recommendation/2478363/Novartis Pharmaceuticals Canada has announced that Beovu (brolucizumab injection) is now available in Canada for the treatment of wet age-related macular degeneration (AMD). The anti-VEGF therapy for wet AMD offers the option for eligible patients to start on 3-mo
- New Company TearRestore Launches Reusable Heat Packs to Target the Meibomian Glandshttps://modernod.com/news/new-company-tearrestore-launches-reusable-heat-packs-to-target-the-meibomian-glands/2478355/New company TearRestore is seeking to simplify warm compress treatment by offering the proprietary TearRestore product. The product utilizes specially designed reusable heat packs to target the Meibomian glands while